October 2022 in “The Korean Journal of Physiology and Pharmacology” This review discusses the roles of prostaglandins in hair loss and highlights their potential as targets for new alopecia treatments, but reports no new clinical findings.
2 citations
,
March 2022 in “Dermatologic Therapy” This study found that using topical latanoprost 0.005% solution significantly increased hair density and regrowth in patients with scalp alopecia areata over 12 weeks, although it did not significantly reduce hair loss area compared to the placebo.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.
November 2020 in “Postepy Dermatologii I Alergologii” This review discusses the potential of using SULT1A1 expression in the scalp as a biomarker to predict response to minoxidil treatment for androgenetic alopecia, but reports no new clinical results.
3 citations
,
September 2019 in “PLOS ONE” In this study, the authors identified the DHRS9 SNP rs72623193 as most significantly associated with response to dutasteride in treating male pattern hair loss, with additional variants potentially contributing.
4 citations
,
May 2019 in “PubMed” This study reported that the expression of sulfotransferase enzymes in hair follicles remained stable during treatment with topical minoxidil, indicating consistent metabolic activity throughout the treatment period.
2 citations
,
February 2019 in “Journal of Investigative Dermatology” This study suggests that the expression of the DP2 receptor is higher in balding scalp cells and that its knockdown could inhibit the transition to the catagen phase in cultured human hair follicles, potentially counteracting hair growth inhibition associated with male pattern baldness.
8 citations
,
February 2019 in “Journal of The European Academy of Dermatology and Venereology” This letter to the editor about prostaglandins in androgenetic alopecia in men and women reports no new research findings.
18 citations
,
February 2018 in “International Journal of Molecular Sciences” This study found that prostaglandin D2 promotes androgen receptor and AKT signaling in human dermal papilla cells through the DP2 receptor, potentially contributing to androgenetic alopecia.
27 citations
,
April 2017 in “British Journal of Dermatology” This study identified overexpression of certain immune-related genes and underexpression of genes in specific signaling pathways in premature androgenetic alopecia, suggesting potential new therapeutic targets.
78 citations
,
January 2017 in “Skin appendage disorders” This review discusses the use of biotin for hair and nail growth, noting clinical improvement in cases with existing pathologies, but concludes there is insufficient evidence supporting its benefits for healthy individuals.
8 citations
,
June 2016 in “Journal of Pharmacy Practice” This case report suggests that lisinopril may cause alopecia, which resolved after the patient switched to losartan potassium.
37 citations
,
October 2015 in “European Journal of Human Genetics” This study found that a genetic model using SNPs can predict early-onset male-pattern baldness with moderate accuracy, which may assist in decisions about interventions.
62 citations
,
January 2015 in “Journal of Dermatological Science” This review summarizes the current genetic research on alopecia areata, including potential new therapeutic strategies, but reports no new clinical findings.
27 citations
,
February 2014 in “Experimental Dermatology” This study found that dermal papilla cells from balding scalp follicles secrete significantly less insulin-like growth factor-1 and its binding proteins, suggesting a mechanism contributing to male pattern baldness.
12 citations
,
December 2013 in “Immunological Investigations” This study suggests that the 5’UTR SNP rs6457452 of HSPA1B may be associated with the onset of Alopecia Areata and reduced susceptibility in the Korean population.
19 citations
,
May 2013 in “Annals of Oncology” This study observed that aromatase inhibitors caused hair loss in menopausal women with breast cancer, mimicking male pattern baldness rather than female androgenetic alopecia.
27 citations
,
December 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” This study found that dexamethasone treatment reduced cell viability and growth factor expression in human dermal papilla cells, suggesting it inhibits hair growth.
54 citations
,
September 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” This study suggests that vitamin A influences the immune response and hair cycle, affecting the progression of alopecia areata in mouse models.
205 citations
,
March 2012 in “Science Translational Medicine” PGD2 stops hair growth and is higher in bald men with AGA.
15 citations
,
June 2011 in “British Journal of Dermatology” This study observed a potential association between the CC genotype of rs4646 and female pattern hair loss, but the authors advise caution due to lack of experiment-wide significance and recommend replication.
100 citations
,
April 2010 in “Expert Opinion on Pharmacotherapy” This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.
77 citations
,
April 2009 in “British Journal of Dermatology” In this study, genetic variation in the CYP19A1 gene, particularly the common rs4646 C allele, was associated with an increased risk of female pattern hair loss, especially in women under 40.
39 citations
,
November 2007 in “Experimental dermatology” This study found that prostaglandin receptors are widely expressed in hair follicles, suggesting a complex network of prostanoid pathways involved in hair growth control.
215 citations
,
November 2006 in “Journal of The American Academy of Dermatology” This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.
139 citations
,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This article reviews androgenetic alopecia in women, highlighting diagnosis criteria and noting that topical minoxidil is currently the only proven treatment for hair growth; it reports no clinical trial findings.
15 citations
,
April 2003 in “Journal of Dermatological Science” This study found no significant associations between the polymorphisms of SRD5A1 and SRD5A2 genes and androgenetic alopecia, clinical types of baldness, or response to finasteride in Koreans.
169 citations
,
June 1998 in “Journal of Investigative Dermatology” This study found no significant genetic association between the 5α-reductase enzyme genes and male pattern baldness, suggesting a polygenic etiology rather than simple inheritance.
6 citations
,
September 1996 in “Journal of the European Academy of Dermatology and Venereology” This study found that biotin supplementation improved biotinidase activity and led to clinical remission in some patients with alopecia areata.
80 citations
,
January 1995 in “The American Journal of Medicine” Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.
20 citations
,
July 1990 in “Journal of the American Academy of Dermatology” Captopril may cause hair loss, as shown by a woman's hair regrowing after stopping the medication.